The drug–gene interaction network analysis in this study identified seven modal genes: DNA topoisomerase II Alpha (TOP2A), Thymidylate Synthetase (TYMS), Survivin (BIRC5), Geminin DNA Replication Inhibitor (GMNN), Cyclin A2 (CCNA2), Aurora Kinase A (AURKA), and Aurora Kinase B (AURKB) that have potential roles in NSCLC treatment. Here, AURKA is linked to non-small cell lung carcinoma.